avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.
Company profile
Ticker
ATXI
Exchange
Website
CEO
Lucy Lu
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Baergic Bio, Inc. ...
ATXI stock data
Latest filings (excl ownership)
S-1
IPO registration
18 Sep 23
8-K
Entry into a Material Definitive Agreement
8 Sep 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
10 Aug 23
8-K
Other Events
21 Jul 23
8-K
Departure of Directors or Certain Officers
5 Jul 23
424B3
Prospectus supplement
28 Jun 23
EFFECT
Notice of effectiveness
28 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
26 Jun 23
CORRESP
Correspondence with SEC
23 Jun 23
Latest ownership filings
SC 13D/A
Fortress Biotech, Inc.
18 Sep 23
4
LINDSAY A MD ROSENWALD
12 Sep 23
4
Change in insider ownership
12 Sep 23
4
Faith L. Charles
5 Jul 23
4
David Jin
5 Jul 23
4
LINDSAY A MD ROSENWALD
5 Jul 23
4
JAY D KRANZLER
5 Jul 23
4
Curtis Gale Oltmans
5 Jul 23
4
Neil Herskowitz
5 Jul 23
4
Alexandra MacLean
3 Jul 23
Financial summary
| Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 1.57 mm | 1.57 mm | 1.57 mm | 1.57 mm | 1.57 mm | 1.57 mm |
| Cash burn (monthly) | 2.22 mm | (no burn) | 1.31 mm | 1.24 mm | 1.56 mm | 913.42 k |
| Cash used (since last report) | 6.26 mm | n/a | 3.68 mm | 3.50 mm | 4.38 mm | 2.57 mm |
| Cash remaining | -4.69 mm | n/a | -2.11 mm | -1.93 mm | -2.81 mm | -1.00 mm |
| Runway (months of cash) | -2.1 | n/a | -1.6 | -1.6 | -1.8 | -1.1 |
Institutional ownership, Q2 2023
82.2% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 14 |
| Opened positions | 5 |
| Closed positions | 2 |
| Increased positions | 0 |
| Reduced positions | 2 |
| 13F shares | Current |
|---|---|
| Total value | 815.64 mm |
| Total shares | 6.73 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| FBIO Fortress Biotech | 5.56 mm | $0.00 |
| Sabby Management | 553.34 k | $647.41 mm |
| CVI Investments | 251.01 k | $0.00 |
| Intracoastal Capital | 216.79 k | $616.00 k |
| BK Bank Of New York Mellon | 52.99 k | $61.99 mm |
| Geode Capital Management | 52.57 k | $60.46 mm |
| STT State Street | 30.59 k | $35.18 mm |
| Tower Research Capital | 5.63 k | $6.59 mm |
| BLK Blackrock | 1.94 k | $2.27 mm |
| Emfo | 533.00 | $624.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 8 Sep 23 | Fortress Biotech | Common Stock | Buy | Acquire P | No | No | 0.72 | 418,410 | 301.26 k | 1,032,390 |
| 8 Sep 23 | Rosenwald Lindsay A MD | Common Stock | Buy | Acquire P | No | No | 0.72 | 348,675 | 251.05 k | 354,318 |
| 29 Jun 23 | Alexandra MacLean | Employee stock option Common Stock | Grant | Acquire A | No | No | 1.14 | 800,000 | 912.00 k | 800,000 |
| 31 Mar 23 | Fortress Biotech | COMMON STOCK, PAR VALUE $0.0001 | Grant | Acquire A | No | No | 0 | 52,419 | 0.00 | 613,980 |
| 3 Jan 23 | Fortress Biotech | COMMON STOCK, PAR VALUE $0.0001 | Grant | Acquire A | No | No | 0 | 231,316 | 0.00 | 561,561 |
| 31 Dec 22 | Fortress Biotech | COMMON STOCK, PAR VALUE $0.0001 | Grant | Acquire A | No | No | 0 | 90,909 | 0.00 | 330,245 |
News
Stocks That Hit 52-Week Lows On Thursday
21 Sep 23
Tongmei, AXT's Subsidiary, Receives Initial Export Permits From China's Central Ministry Of Commerce For Gallium Arsenide And Germanium Substrates
20 Sep 23
Stocks That Hit 52-Week Lows On Friday
8 Sep 23
Stocks That Hit 52-Week Lows On Thursday
7 Sep 23
Stocks That Hit 52-Week Lows On Wednesday
30 Aug 23
Press releases
Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
5 Sep 23
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
14 Aug 23
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
10 Aug 23
Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study
1 Aug 23
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
27 Jul 23